RESEARCH ARTICLE

Generation of a pancreatic cancer model using a Pdx1-Flp recombinase knock-in allele

Jinghai Wu1,2*, Xin Liu1,2, Sunayana G. Nayak1,2, Jason R. Pitarresi1,2, Maria C. Cuitiño1,2, Lianbo Yu3, Blake E. Hildreth, III4,5, Katie A. Thies4,5, Daniel J. Schilling1,2, Soledad A. Fernandez3, Gustavo Leone4,5, Michael C. Ostrowski4,5*

1 Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America, 2 Cancer Biology and Genetics Department, The Ohio State University, Columbus, Ohio, United States of America, 3 Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio, United States of America, 4 Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America, 5 Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina, United States of America

* ostrowsk@musc.edu (M.C.O.); Jinghai.Wu@osumc.edu (J.W.)

Abstract

The contribution of the tumor microenvironment to the development of pancreatic adenocarcinoma (PDAC) is unclear. The LSL-KrasG12D/+;LSL-p53R172H/+;Pdx-1-Cre (KPC) tumor model, which is widely utilized to faithfully recapitulate human pancreatic cancer, depends on Cre-mediated recombination in the epithelial lineage to drive tumorigenesis. Therefore, specific Cre-loxP recombination in stromal cells cannot be applied in this model, limiting the in vivo investigation of stromal genetics in tumor initiation and progression. To address this issue, we generated a new Pdx1FlpO knock-in mouse line, which represents the first mouse model to physiologically express FlpO recombinase in pancreatic epithelial cells. This mouse specifically recombines Frt loci in pancreatic epithelial cells, including acinar, ductal, and islet cells. When combined with the Frt-STOP-Frt KrasG12D and p53Frt mouse lines, simultaneous Pdx1FlpO activation of mutant Kras and deletion of p53 results in the spectrum of pathologic changes seen in PDAC, including PanIN lesions and ductal carcinoma. Combination of this KPF mouse model with any stroma-specific Cre can be used to conditionally modify target genes of interest. This will provide an excellent in vivo tool to study the roles of genes in different cell types and multiple cell compartments within the pancreatic tumor microenvironment.

Introduction

Conditional gene knockout is a powerful tool to study the role of individual genes in living organisms. This technique eliminates many of the side effects associated with conventional gene knockout, such as embryonic lethality and the lack of tissue specificity, among others. A conditional knockout approach controls excision of the endogenous target DNA through site-specific recombination (SSR), which involves a recombinase and its short DNA recognition site. The most commonly used site-specific recombinases include Cre (of bacteriophage P1),
Flp (of the yeast *Saccharomyces cerevisiae*) and Dre (of bacteriophage D6). These recombinase enzymes recognize 34 bp Loxp, 34 bp Frt, and 32 bp Rox target sites, respectively, and catalyze a reciprocal conservative recombination between two identical target sequences. This recombination results in a sequence deletion between the two target sites. Although initial studies showed that Cre and Dre were more efficient recombinases than Flp in mammalian cells, a codon optimized version of Flp (termed FlpO), has greatly improved its reliability [1, 2]. Because Cre, Flp, or Dre recombinases are not expressed in mammalian cells, there is no risk of accidental target site recombination in conditional gene knockout mice. Therefore, conditional gene knockout mice are often used as models of human diseases. It has also tremendously increased our ability to study complex human diseases in specific developmental stages and tissues through spatial or temporal gene inactivation via DNA excision. In addition, through combination of different SSR systems within the same model, we can achieve spatiotemporal control of distinct genetic ablation/induction because of independent regulation of distinct recombinases.

PDAC is among the most deadly malignant solid tumors, with over 95% of patients succumbing to the disease within five years of diagnosis, which is largely the result of no effective therapies beyond surgery [3, 4]. The most prominent histopathologic hallmark of pancreatic cancer is its uniquely dense stromal reaction, which consists of activated fibroblasts, increased amounts of extra-cellular matrix (ECM), immune cell infiltrates, and abnormal angiogenesis [5]. The stroma undergoes a dramatic expansion in concert with the stepwise development of PDAC, suggesting that the stroma is an active player in PDAC progression. This has sparked interest in selectively targeting the tumor stroma to increase therapeutic efficacy. However, current knowledge of how the stroma influences tumor initiation, growth, and metastasis remains rudimentary. While current mouse models such as the *LSL-Kras*\(^{G12D/+}\);*LSL-p53*\(^{R172H/+}\);*Pdx-1-Cre* (KPC) model accurately reflect the genetics of pancreatic tumor cells and human tumor progression [6–8], these models depend on epithelial-specific Cre-mediated recombination to drive tumorigenesis. Therefore, concurrent Cre-loxP recombination in stromal cells is not practical in these models, limiting the in vivo study of stromal genetics in tumor initiation and progression. Thus, the development of mouse models that incorporate stroma-specific genetic modifications in an autochthonous tumor system is crucial to the advancement of the PDAC field. To address this issue, the ideal strategy would be to combine an alternative recombinase system in epithelial cells with Cre-loxP in stromal cells, since *Frt-STOP-Frt(FSF)* *Kras*\(^{G12D}\) and *p53*\(^{frt/frt}\) animals are available. Therefore, we set to develop a knock-in mouse model termed as *Pdx1FlpO*, in which the FlpO gene is specifically inserted into the transcriptional start site of pancreas-duodenum homeobox 1 (*Pdx1*). We then combined this *Pdx1FlpO* mice with the above mentioned lines to generate a Flp/Frt PDAC mouse model, *Pdx1FlpO*\(^{Fr}\);*FSF-Kras*\(^{G12D/+}\);*p53*\(^{frt/frt}\) (KPF), which is comparable to the historical KPC tumor model.

A transgenic *PdxFlpO* mouse model was recently reported [9]. However, two lines of these *PdxFlpO* mice showed the transgene located in chromosome 1 and 12, while the normal physiologic location of the *Pdx1* gene is chromosome 5. With these different chromosomal integration sites, FlpO expression may be influenced by transcriptional regulators other than authentic pancreas-specific regulators. Therefore, the effects of FlpO recombination on mutant Kras and p53 activation may have off-target effects other than normal *Pdx1* residential tissues (pancreas, duodenum, and bile duct).

The results presented herein demonstrate the exclusive expression of FlpO in *Pdx1* expressing tissues in our knock-in *PdxFlpO* mouse model. FlpO is only expressed in duodenal epithelium, pancreatic acinar cells, ductal cells, and islet cells with no expression in the stroma. This provides an excellent model to investigate genes of interest specifically in stromal cells when
combined with stroma-specific Cre-loxP. The knock-in p53 heterozygous and homozygous mice (KPF) develop the spectrum of pathologic changes seen in human PDAC, including acinar to ductal metaplasia (ADM), pancreatic intraepithelial neoplasia (PanIN) and invasive ductal carcinoma, with average survival times of 4.5 and 2 months, respectively. Moreover, the variability of the average survival times is small when compared to published transgenic KPF models, indicating a highly reliable and reproducible KPF model. In summary, this newly developed knock-in KPF mouse model is a valuable tool for studying stromal tissue-specific function of genes of interest in the pancreatic tumor microenvironment.

**Results**

**Generation of Pdx1FlpO\textsuperscript{ki} mouse line**

Codon usage-optimized Flp (FlpO) cDNA linked with beta-globin polyA was fused into the start codon site of the Pdx1 gene, replacing the CFP in the previously generated Pdx1CFP targeting vector [10]. A LoxP-Neo\textsuperscript{R}-LoxP (LNL) fragment was introduced to select neomycin resistant clones, while a DNA fragment containing mouse phosphoglycerol kinase promoter (Pgk)-driven expression of thymidine kinase was inserted outside of the short arm for negative selection. Therefore, this targeting allele contained the mouse Pdx1 long homology arms of 8.1kb, FlpO cDNA/beta-globin polyA, flanked neomycin resistant cassette (LNL), Pdx1 short arm of 3.6kb and a Pgk-TK cassette, respectively (Fig 1A). Homologous recombination resulted in replacement of a 4.0 kb region of the Pdx1 locus containing exon 1 with codon usage-optimized FlpO cDNA, human beta-globin polyA, and a Pgk-driven neomycin resistance gene flanked by LoxP sites. Clones of interest that had undergone the expected homologous recombination were identified by a 19.0 kb band after digestion with HindIII after hybridization with a 5’ probe, and a band of 7.2 kb after digestion with AflII hybridized with a 3’ probe (ES cell clone #3, Fig 1B). After microinjection of positive ES cell clone WO3 into blastocysts of C57BL/6 mice, the first generation (F0) of Pdx1FlpO\textsuperscript{LNL} mice was examined by genotyping PCR using primers targeting allele recombination in both the 5’ and 3’ arms. Correctly recombined clones were identified by 0.4 and 1.1 kb bands on the 5’ and 3’, respectively (Fig 1C). The LoxP-flanked NeoR sequence in Pdx1FlpO\textsuperscript{LNL} (F0) mice was further removed by breeding to Sox2-Cre mice. The resultant Pdx1FlpO\textsuperscript{knockin} (denoted PdxFlpO\textsuperscript{ki}) allele was maintained in a mixed background.

**In vivo expression specificity test of the Pdx1FlpO allele**

To evaluate the expression of FlpO recombinase in multiple tissues, we crossed our Pdx1FlpO\textsuperscript{ki} mouse with the p53\textsuperscript{frt/frt} mouse, of which exons 2–6 of the p53 gene are flanked by two Frt sites [11]. After collecting all tissues from Pdx1FlpO\textsuperscript{ki,p53\textsuperscript{frt/+}} mice, we observed recombination of the p53 Frt allele in the pancreas, duodenum, and bile duct by PCR (Fig 2A). Spleen, heart, lung, skin, liver, stomach, colon, and kidney demonstrated no recombination (Fig 2A). To further validate this model, we crossed Pdx1FlpO\textsuperscript{ki} mice with Frt-stop-Frt (FSF)-GFP reporter mice. Immunohistochemical (IHC) staining for GFP on tissues isolated from Pdx1FlpO\textsuperscript{ki} mice revealed GFP expression in the pancreas, duodenum and bile duct but not in the stomach and other tissues (Fig 2B and data not shown). More specifically, GFP expression in the adult pancreas is mosaic and present in a fraction of ductal cells, islet cells, and acinar cells (Fig 2B and Figure A in S1 Fig). This is consistent with the previous reports using Pdx1-Cre and Pdx1-FlpO transgenic mice. In addition, there was no GFP expression in control FSF-GFP mice. Taken together, these data suggest that Pdx1FlpO knockin allele expression is restricted to the pancreas, duodenum, and bile duct.
Next, we tried to activate the KrasG12D allele and silence the p53 allele in murine pancreatic progenitor cells by crossing Pdx1FlpOki, FSF-KrasG12D/+ and p53frt/+ mice. To confirm the induction of Pdx1 in early pancreatic lesions, we evaluated Pdx1 expression in 3-month old Pdx1FlpOi;FSF-KrasG12D/+;p53frt/+;FSF–GFP mice. IHC staining for Pdx1 in pancreatic tissue

Pdx1FlpOki;FSF-KrasG12D/+;p53frt/+ mice develop locally advanced PDAC and have a significant reduction in survival time.
**Fig 2. In vivo Pdx1FlpO<sup>ki</sup> allele expression specificity.** (A) PCR analysis of Pdx1FlpO<sup>ki</sup> mediated recombination of the p53Frt allele in the indicated tissues of Pdx1FlpO<sup>ki</sup>; p53<sup>Frt/+</sup> mice. (B) Representative GFP IHC staining demonstrates mosaic GFP expression in the pancreas and duodenum, but not the stomach, of Pdx1FlpO<sup>ki</sup>; FSF-GFP mice. Scale bars = 25 μm.

https://doi.org/10.1371/journal.pone.0184984.g002
revealed robust Pdx1 expression in PanIN lesions (Figure B in S1 Fig), indicating that Pdx1 induction occurs in PanIN lesions in our KPF mouse model. Further, losing one p53 allele, i.e. Pdx1FlpO<sup>ki</sup>; FSF-Kras<sup>G12D</sup>/+; p53<sup>frt/+</sup>, results in a marked decrease in median survival time (~4.5 months) when compared with their control littermates (Pdx1FlpO<sup>ki</sup>; FSF-Kras<sup>G12D</sup>/+ animals) (Fig 3A and 3B). This entire cohort of mice (n = 20) showed invasive PDAC at necropsy. Loss of two p53 alleles, i.e. Pdx1FlpO<sup>ki</sup>; FSF-Kras<sup>G12D</sup>/+; p53<sup>frt/frt</sup>, resulted in an even greater decrease in median survival (~2 months). Interestingly, our KPF mouse model showed a significant reduction in survival time when compared to established transgenic KPF models [9], with a median survival of 135 days versus 183 days in the KPF model in P53<sup>frt/+</sup> animals and a median survival of 60 days versus 85 days in the KPF model in P53<sup>frt/frt</sup> animals. This likely results from our Pdx1FlpO model possessing a knock-in allele instead of transgenic allele that is present in the KPF model. Histologically, Pdx1FlpO<sup>ki</sup>; FSF-Kras<sup>G12D</sup>/+; p53<sup>frt/+</sup> mice developed classical PanIN lesions and PDAC. At 2–3 months of age, both low and high grade PanIN lesions were observed, but by 6 months, invasive carcinoma was present (Fig 4A and 4B). The average weight of the pancreas in Pdx1FlpO<sup>ki</sup>; FSF-Kras<sup>G12D</sup>/+; p53<sup>frt/+</sup> and Pdx1FlpO<sup>ki</sup>; FSF-Kras<sup>G12D</sup>/+; p53<sup>frt/frt</sup> mice increased significantly compared to Pdx1FlpO<sup>ki</sup>; FSF-Kras<sup>G12D</sup>/+ mice (See S1 Table for details). However, unlike previously described transgenic KPC and KPF mouse models, which exhibit metastasis to the liver and lung, we observed negligible metastasis to distant organs, with no lung and only two liver metastases upon evaluation of 53 of our Pdx1FlpO<sup>ki</sup>; FSF-Kras<sup>G12D</sup>/+; p53<sup>frt/+</sup> and Pdx1FlpO<sup>ki</sup>; FSF-Kras<sup>G12D</sup>/+; p53<sup>frt/frt</sup> mice combined (Table 1).

**Discussion**

In the last decade, significant advances have been made in understanding the molecular mechanisms underlying human pancreatic cancer using genetically-engineered PDAC mouse models. Compared to xenograft mouse models, these GEM models strongly resemble the histopathology of human PDAC development, providing a great tool to evaluate preclinical therapeutic strategies for the treatment of pancreatic cancer.
Fig 4. p53 knockout accelerates PDAC formation. (A) Representative macroscopic view of pancreata from PdxFlpO\textsuperscript{O};FSF-Kras\textsuperscript{G12D};p53\textsuperscript{Frt/+} mice at 3 and 6 months of age. (B) Representative microscopic H&E stained pancreatic sections from PdxFlpO\textsuperscript{O};FSF-Kras\textsuperscript{G12D};p53\textsuperscript{Frt/+} mice at 3 and 6 months. Scale bars = 25 μm.

https://doi.org/10.1371/journal.pone.0184984.g004

Table 1. Metastasis spectrum in knock-in KPF mice.

|                  | Total Number | Liver Metastasis | Lung Metastasis |
|------------------|--------------|------------------|-----------------|
| PdxFlpO\textsuperscript{O};FSF-Kras\textsuperscript{G12D};p53\textsuperscript{Frt/+} | 20           | 2                | 0               |
| PdxFlpO\textsuperscript{O};FSF-Kras\textsuperscript{G12D};p53\textsuperscript{Frt/+} | 33           | 0                | 0               |

https://doi.org/10.1371/journal.pone.0184984.t001
All PDAC GEM models are based on Kras activating mutations combined with additional deletions or mutations of other PDAC suppressors such as p53, Smad4, Tgf-β or PTEN [12, 13]. The most widely used and accepted model is the Pdx1-Cre;LSL-Kras\(^{G12D/+}\); LSL-p53\(^{R172H/+}\) transgenic mouse of which mutated Kras and p53 are specifically expressed in pancreatic progenitor cells and are driven by the transcription factor Pdx1. However, due to the nature of Cre-LoxP technology, this model is limited in regards to elucidating the function of other gene targets in different cell types present within the tumor, e.g. in the stromal mesenchymal and immune cell subpopulations. More recently, the generation of KPF mice has provided a solution for this issue. This model uses an alternative Flp/Frt-based recombinase system in the stroma to drive spontaneous PDAC and possesses similar pathology as the KPC mouse model [9]. By combining these two complementary recombinase strategies, gene expression can be manipulated simultaneously in different cell types present within the tumor. This will contribute significantly to the understanding of the relationship between stroma and PDAC progression in a more mechanistic manner.

However, both KPC and existing KPF mouse models are transgenic mice. Compared to a knock-in mouse model which is “specifically targeted”, transgenic models are well known for their “random integration”–the desired gene could end up anywhere in the host genome and with an unpredictable amount of copy numbers inserted. This “randomness” of transgenic models is a limitation due to their unpredictability since the desired gene might be placed under the influence of another strong promoter with a high copy number. Unpredictable levels of overexpression could lead to high variability in the magnitude of the disease [14]. Thus, it might not serve as a reliable and reproducible model of human disease. In addition, studies have demonstrated the leakiness of the previously reported transgenic PdxCre allele in other tissues, most notably in gastric and oral mucosa, which has led to the development of extrapancreatic tumors such as papillomas and adenomas [7, 14].

In this study, we generated a Pdx1FlpO knock-in mouse line. The Pdx1 gene is expressed in pancreatic progenitor cells starting at embryonic day (E) 8.5. As development proceeds, Pdx1 becomes highly expressed in β cells with lower levels expressed in acinar and other endocrine cells [15]. The mosaic Cre-mediated recombination that occurs within the pancreas using the Pdx1 enhancer/promoter is well established [16]. More importantly, expression of Pdx1-Cre has also been shown in skin keratinocytes [17]. By breeding with the FSF-GFP mouse line, we verified that our knock-in Pdx1FlpO demonstrated a similar mosaic expression pattern within acinar, ductal and islet cells in a lineage-specific manner which is consistent between littermates. More importantly, in contrast to Pdx1-Cre, we did not observe Pdx1-FlpO expression in the skin. This finding suggests that the leakiness identified in Pdx1-Cre mice might be due to its transgenic targeting strategy.

Compared to the existing transgenic KPF model [9], our knock-in KPF mouse had a decreased survival time. The discrepancies between these two studies could be the timing of FlpO recombinase expression, extension of recombinase expression, genetic background, etc. The timing of FlpO expression in the existing transgenic model was not described [9]. Previous work in the literature demonstrates that the regulatory elements used to generate both PdxCre and PdxFlpO transgenic alleles were sufficient to drive pancreatic expression of Pdx1 alleles with the same developmental timing as the endogenous gene [18], although the location of transgene insertion may affect the timing of expression. Thus, it is difficult to predict when expression began since this transgene was located in Chromosome 12C1-3 instead of the physiological locus of Chromosome 5. In contrast, our knock-in FlpO was located in the normal physiological location of the Pdx1 gene (Chromosome 5). Publications from different labs characterized the expression pattern of Pdx1 \textit{in vivo} using knock-in mouse models [10, 19]. Micallef et al presented a knock-in GFP reporter in the endogenous Pdx1 locus, a strategy...
similar to our Pdx1FlpO model [19]. Their pattern of GFP expression was identical to that reported for the endogenous Pdx1 gene (E9.5, in the dorsal and ventral pancreatic anlage) [20–22], with GFP not being detected in other embryonic tissues. In addition, similar phenotypes were observed in a well-characterized Pdx1CFP mouse line [10], in which CFP was also inserted into exon 1 of the Pdx1 locus by homologous recombination. Both Pdx1 and CFP were detected in the dorsal and ventral endodermal evaginations of the posterior foregut at E9.5. From E10.5 to E11.5, Pdx1 and CFP were detected throughout the pancreatic epithelium. They concluded that this faithfully recapitulated the normal physiologic expression of endogenous Pdx1. Using their knock-in targeting vector Pdx1CFP as a backbone, we successfully replaced the Pdx1 reporter-cyan fluorescent protein (CFP) with FlpO recombinase in our knock-in Pdx1FlpO mouse line. Because the literature already extensively documents the timing of expression of reporter genes knocked into this locus with identical strategies, it is reasonable to predict that the timing of the initiation of FlpO recombinase expression in our mouse model should be the same as it is normally for Pdx1 expression in vivo. In addition, in our adult knock-in Pdx1FlpO mice, Pdx1-induced FlpO recombination resulted in GFP expression in PanIN lesions. This indicated that Pdx1 induction is present exclusively in the epithelial lesions of our adult KPF tumor model. These findings are consistent with the previous reports using Pdx1Cre (7) and Pdx1FlpO transgenic mice [9].

PDAC is a cancer type in which mutant p53 impacts disease progression. In addition to the most frequent Kras gene mutation, the p53 gene is also often mutated in human pancreatic cancer in 50–75% of cases [23, 24], predominantly through missense mutations such as R175H and R273H. Consistent with a role for mutant p53 in other mouse models, mice bearing PDAC driven by oncogenic Kras and a mutant p53 allele have shown a greater number of metastases compared to similar mice bearing a p53 null allele [25], likely resulting from up-regulation of PDGFR-β [26]. A full spectrum of PDAC tumorigenesis, including PanINs and carcinoma, were observed in every single mouse in our study cohorts. However, we have detected minimal metastasis to distant organs (2 liver metastases out of 53 mice), with loss of either one or both p53 alleles. This is consistent with other reports on cancer metastasis in mice harboring a p53 null allele, and likely results from ablating the p53 gene instead of activating p53 mutations in the pancreatic epithelium. Of note, there is no FSF-p53 mutant model available currently. In the future, generation of the FlpO-activated p53 mutant mouse line would greatly benefit this alternative KPF pancreatic cancer model to evaluate metastasis.

Taken together, our knock-in Pdx1FlpO<sup>ki</sup> line is more stable and tissue-specific when compared to existing transgenic mouse lines. Thus, it has the potential to contribute to 1) studies evaluating therapeutics at different stages of tumor progression; 2) determining the interaction between multiple tumor suppressors and oncogenes; and 3) the development of new diagnostic approaches. Notably, this Pdx1FlpO model is not inducible; therefore, it will be desirable to develop a conditional knock-in model. This latter system would allow investigators to turn on/off genes using this recombinase at discrete time points, such as in adulthood. Future studies should also investigate its compatibility with Cre-loxP targeting of genes of interest in stromal populations.

**Materials and methods**

**Pdx1FlpO knock-in targeting**

To avoid potential self-recombination by FlpO (Codon usage-optimized Flp), the Frt-hygroR-Frt fragment was initially removed from the Pdx1<sup>CFP+HygroR</sup> exchange vector [10] by NotI digestion and subsequent re-ligation. A PCR-amplified FlpO fragment from pCAGGs-FlpO [2] was cloned into the ATG start codon site of the Pdx1 gene in the Pdx1<sup>CFP</sup> vector,
followed by insertion of a blunted LoxP-Neo-LoxP (LNL) fragment into the MluI site. A thymidine kinase (TK) cassette was acquired from EcoRI/PvuII digestion of the pLMJ322 vector. The TK fragment was blunted and ligated into the MluI digested Pdx1FlpO-LNL vector, which resulted in the final targeting vector. This targeting vector was named Pdx1FlpO-LNL-TK. The sequence of the full construct (denoted JW9) was confirmed (3730 DNA Analyzer, Applied Biosystems).

Gene targeting was performed following standard protocols by the Genetically Engineered Mouse Modeling facility at The Ohio State University James Comprehensive Cancer Center. In brief, 1 mg of targeting vector linearized with NotI was electroporated into mouse S1B6 (hybrid C57Bl/6-129Sv) ES cells. Following neomycin selection, homologous recombination was verified by Southern blot. A DNA fragment of 19.0 kb that includes most of the long arm, the FlpO cDNA, the Pkg-neo cassette, and the entire short arm was detected using a 5’ probe, while a HindIII-digested fragment of 15 kb from the WT Pdx1 allele was detected in all ES cells. In contrast, an AflII-digested fragment of 7.2 kb from the FlpO knockin allele was detected using a 3’ probe and generated a fragment of 4.8 kb from the WT Pdx1 allele. Germ-line transmission was achieved following the microinjection of clone WO3 mES cells into C57BL/6 blastocysts. Chimeras were crossed to Black Swiss.

Other mouse strains and tumor models

*Kras*<sup>FSE-G12D/+</sup> mice were kindly provided by Tyler Jacks. *p53<sup>frt/+</sup>* and *Rosa<sup>LSL-FLF-GFP</sup>* mice have been described previously [9, 11]. Unless otherwise stated, animals were on a mixed C57Bl/6;129Sv;Black Swiss background. *Pdx1FlpO<sup>Lk</sup>*<sup>FSE-Kras<sup>G12D/+</sup></sup> and *p53<sup>frt/+</sup>* were interbred to obtain PDAC mice (KPF) with activation of oncogenic *Kras<sup>G12D</sup> and deletion of *p53* in the pancreatic epithelium. All animal experimental protocols were approved by the Ohio State University Institutional Animal Care and Use Committee. Mice were monitored and weighed weekly. Control mice (*Pdx1FlpO<sup>Lk</sup>*<sup>FSE-Kras<sup>G12D/+</sup></sup>) and experimental mice (*Pdx1FlpO<sup>Lk</sup>*<sup>FSE-Kras<sup>G12D/+</sup>, p53<sup>frt/+</sup></sup> and *Pdx1FlpO<sup>Lk</sup>*<sup>FSE-Kras<sup>G12D/+</sup>, p53<sup>frt/frt</sup></sup>) were euthanized with carbon dioxide (CO2) and cervical dislocation by 6 months of age. Mice were removed sooner when they met Early Removal Criteria (ERC) which included an unkempt hair coat, decreased alertness and mobility, reduced food and water intake, and a 20% loss of body weight if any of these symptoms persisted for more than 24 hrs. The overall health of the animals was monitored by our trained laboratory personnel and the veterinary staff.

Histologic analysis and immunohistochemistry

Dissected mouse pancreata were fixed in 10% neutral-buffered formalin for 48 hr and then transferred to 70% ethanol. Tissues were processed, embedded in paraffin, cut in 5μm sections on positively charged slides, de-paraffinized, rehydrated, and stained with H&E. For GFP IHC, slides were heated at 65˚C for 15 min and after standard de-paraffinization and rehydration, sections were unmasked in 1X Target Retrieval solution (pH = 6.0). Endogenous peroxidases were quenched in 3% H<sub>2</sub>O<sub>2</sub>/PBS for 15 min. Primary antibody incubation was performed overnight (16 hr) at 4˚C. Staining for GFP was preformed using an immunoperoxidase technique (Vectastain Elite ABC kit, Vector Labs) and 3,3’-diaminobenzidine followed by counterstaining with Meyer’s hematoxylin. After counterstaining, samples were dehydrated through ethanol and xylenes, mounted and cover slipped. Pdx1 IHC was performed using the Bond RX autostainer (Leica Biosystems Inc.). For this, slides were baked at 65˚C for 15 minutes and the automated system performed dewaxing, rehydration, antigen retrieval, blocking, primary antibody incubation, post primary antibody incubation, detection (DAB), and counterstaining using Bond reagents (Leica). The following primary antibodies were used: rabbit anti-GFP.
PCR genotyping

To identify the Pdx1-FlpO knock-in allele, a genotyping strategy was designed including both the 5' and 3' ends (Fig 1A). Primer sequences were: P1: 5'-GGAGAAGTCAAACGCATTCCATC-3'; P2: 5'-GGAGCCTGTCAGACTCAGG-3'; P3: 5'-CTTAGGCGGTTCTTGGATTAG-3'; P4: 5'-TCGACTGTGCTTTCTAGTTG-3'. For the 5' end, the wild type allele amplified by primer pair P1–P2 produces a PCR product of 576 bp whereas the Pdx1-FlpO allele amplified by primer pair P1–P3 gives a 1100 bp product. For the 3' end, the wild type allele amplified by primer pair P1–P2 produces a PCR product of 576 bp whereas the Pdx1-FlpO allele amplified by primer pair P2–P4 gives a 399 bp product. All PCR reactions were performed using the following conditions: 94°C for 1 min followed by 35 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C 1 min.

Supporting information

S1 Fig. Percentage of recombination in the pancreas and representative Pdx1 immunohistochemistry. (A) The percentage of recombination in the pancreas. The recombination was quantified by percentage of GFP positive cells in three pancreatic epithelial lineages (ductal cells, islet cells and acinar cells), N = 3 and (B) Representative Pdx1 immunohistochemistry staining demonstrates Pdx1 expression in the pancreatic PanIN lesions (Black arrows) of Pdx1FlpO[+]:FSF-KrasG12D/+;p53frt/+;FSF–GFP mice (scale bar: 50 μm). (PPTX)

S1 Table. Tumor and animal data. (XLSX)

Acknowledgments

The authors thank Dr. Tyler Jacks (Massachusetts Institute of Technology), Dr. David Kirsch (Duke University) for providing transgenic animals; Dr. Mark Magnuson (Vanderbilt University) for providing Pdx1CFP vector [10]; Dr. A. Francis Stewart for providing pCAGGs-FlpO vector [2]; Dr. V. Coppola (Genetically Engineered Mouse Modeling facility of The Ohio State University James Comprehensive Cancer Center) for helping mouse targeting; Shannon K. Halloran, and Maokun Li for helping mouse housing and genotyping. This study was supported by NIH PO1 CA097189 (M.C.O. and G.L.).

Author Contributions

Conceptualization: Jinghai Wu, Gustavo Leone, Michael C. Ostrowski.

Data curation: Lianbo Yu, Blake E. Hildreth, III, Katie A. Thies.

Formal analysis: Jinghai Wu, Xin Liu.

Funding acquisition: Michael C. Ostrowski.

Investigation: Jinghai Wu, Xin Liu, Daniel J. Schilling, Michael C. Ostrowski.

Methodology: Jinghai Wu, Gustavo Leone, Michael C. Ostrowski.
**Project administration:** Jinghai Wu, Michael C. Ostrowski.

**Resources:** Soledad A. Fernandez, Michael C. Ostrowski.

**Supervision:** Michael C. Ostrowski.

**Validation:** Jinghai Wu, Xin Liu, Sunayana G. Nayak, Jason R. Pitarresi, Maria C. Cuitiño, Soledad A. Fernandez.

**Visualization:** Xin Liu, Sunayana G. Nayak, Jason R. Pitarresi, Maria C. Cuitiño.

**Writing – original draft:** Jinghai Wu, Xin Liu, Michael C. Ostrowski.

**Writing – review & editing:** Jinghai Wu, Blake E. Hildreth, III, Katie A. Thies, Michael C. Ostrowski.

**References**

1. Hoang TT, Karkhoff-Schweizer RR, Kutchma AJ, Schweizer HP. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. *Gene*. 1998; 212: 77–86. PMID: 9661666

2. Kranz A, Fu J, Duerschke K, Weidlich S, Naumann R, Stewart AF, et al. An improved Flp deleter mouse in C57Bl/6 based on Flipo recombinase. *Genesis*. 2010; 48: 512–520. https://doi.org/10.1002/dvg.2050501

3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin*. 2013; 63: 11–30. https://doi.org/10.3322/caac.21616 PMID: 23335087

4. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse S, et al. SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD, 2013. https://seer.cancer.gov/csr/1975_2010/.

5. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. *Clin Cancer Res*. 2012; 18: 4266–4276. https://doi.org/10.1158/1078-0432.CCR-11-3114 PMID: 22896693

6. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell*. 2003; 4: 437–450. PMID: 14706336

7. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell*. 2005; 7: 469–483. https://doi.org/10.1016/j.ccr.2005.04.023 PMID: 15894267

8. Perea–Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. *Gastroenterology*. 2012; 142: 1079–1092. https://doi.org/10.1053/j.gastro.2012.03.002 PMID: 22406637

9. Schönhuber N, Seidl B, Schuck K, Veltkamp C, Schachtler C, Zukowska M, et al. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. *Nat Med*. 2014; 20: 1340–1347. https://doi.org/10.1038/nm.3648 PMID: 25326799

10. Potter LA, Choi E, Hipkens SB, Wright CV, Magnuson MA. A recombinase-mediated cassette exchange-derived cyan fluorescent protein reporter allele for Pdx1. *Genesis*. 2012; 50: 384–392. https://doi.org/10.1002/dvg.20804 PMID: 21913313

11. Lee C-L, Moding EJ, Huang X, Li Y, Woodlife LZ, Rodrigues RC, et al. Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice. *Dis Model Mech*. 2012; 5: 397–402. https://doi.org/10.1242/dmm.00984 PMID: 2228755

12. Ostafoff KT, Dellingner MT, Awasthi N, Brekken RA, Schwarz RE. Mouse models of pancreatic cancer. In: Malek A, editor. Experimental metastasis: modeling and analysis: Springer; 2013. pp. 57–91.

13. Guerra C, Barbacid M. Genetically engineered mouse models of pancreatic adenocarcinoma. *Mol Oncol*. 2013; 7: 232–247. https://doi.org/10.1016/j.molonc.2013.02.002 PMID: 23306980

14. Doyle A, McGarry MP, Lee NA, Lee JJ. The construction of transgenic and gene knockout/knockin mouse models of human disease. *Transgenic Res*. 2012; 21: 327–349. https://doi.org/10.1007/s11248-011-9537-3 PMID: 21800101
15. Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H. β-Cell-specific inactivation of the mouseIpf1/Pdx1 gene results in loss of the β-cell phenotype and maturity onset diabetes. Genes Dev. 1998; 12: 1763–1768. PMID: 9637677
16. Gannon M, Herrera PL, Wright C. Mosaic Cre-mediated recombination in pancreas using the pdx-1 enhancer/promoter. Genesis. 2000; 26: 143–144. PMID: 10686611
17. Mazur PK, Grüner BM, Nakhai H, Sipos B, Zimber-Strobl U, Strobl LJ, et al. Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine Kras G12D-induced skin carcinogenesis in vivo. PLoS One. 2010; 5: e13578. https://doi.org/10.1371/journal.pone.0013578 PMID: 21042537
18. Gannon M, Gamer LW, Wright CV. Regulatory regions driving developmental and tissue-specific expression of the essential pancreatic gene pdx1. Dev Biol. 2001; 238: 185–201. https://doi.org/10.1006/dbio.2001.0359 PMID: 11784003
19. Micallef SJ, Janes ME, Knezevic K, Davis RP, Elefanty AG, Stanley EG. Retinoic acid induces Pdx1-positive endoderm in differentiating mouse embryonic stem cells. Diabetes. 2005; 54: 301–305. PMID: 15585742
20. Ahlgren U, Jonsson J, Edlund H. The morphogenesis of the pancreatic mesenchyme is uncoupled from that of the pancreatic epithelium in IPF1/PDX1-deficient mice. Development. 1996; 122: 1409–1416. PMID: 8625829
21. Murtaugh LC, Melton DA. Genes, signals, and lineages in pancreas development. Annu Rev Cell Dev Biol. 2003; 19: 71–89. https://doi.org/10.1146/annurev.cellbio.19.111301.144752 PMID: 14570564
22. Ohlsson H, Karlsson K, Edlund T. IPF1, a homeodomain-containing transactivator of the insulin gene. EMBO J. 1993; 12: 4251–4259. PMID: 7901001
23. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett. 1993; 69: 151–160. PMID: 8513440
24. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006; 20: 1218–1249. https://doi.org/10.1101/gad.1415606 PMID: 16702400
25. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A. 2010; 107: 246–251. https://doi.org/10.1073/pnas.0908428107 PMID: 20018721
26. Weissmueller S, Manchado E, Saborowski M, Morris JP, Wagenblast E, Davis CA, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell. 2014; 157:382–394. https://doi.org/10.1016/j.cell.2014.01.066 PMID: 24725405